Bradley Campbell Sells 22,500 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley Campbell sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $14.35, for a total value of $322,875.00. Following the completion of the sale, the chief executive officer owned 998,680 shares in the company, valued at $14,331,058. The trade was a 2.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Amicus Therapeutics Stock Down 0.1%

Shares of NASDAQ FOLD traded down $0.01 during midday trading on Wednesday, reaching $14.33. The company’s stock had a trading volume of 5,574,167 shares, compared to its average volume of 5,182,985. The stock has a 50 day simple moving average of $14.30 and a 200-day simple moving average of $10.83. The company has a current ratio of 2.84, a quick ratio of 1.88 and a debt-to-equity ratio of 1.43. The stock has a market capitalization of $4.50 billion, a price-to-earnings ratio of -179.13 and a beta of 0.43. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $14.38.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The business had revenue of $185.21 million during the quarter, compared to the consensus estimate of $185.00 million. During the same period last year, the business posted $0.09 EPS. The firm’s revenue for the quarter was up 23.7% on a year-over-year basis. Equities research analysts predict that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on FOLD shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Monday, December 29th. Zacks Research cut Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 26th. Wall Street Zen raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Citigroup restated a “neutral” rating and set a $14.50 target price (down from $17.00) on shares of Amicus Therapeutics in a report on Monday, December 22nd. Finally, Needham & Company LLC lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 19th. Three analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Amicus Therapeutics currently has an average rating of “Hold” and an average price target of $15.39.

Institutional Investors Weigh In On Amicus Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. HBK Investments L P acquired a new position in shares of Amicus Therapeutics in the fourth quarter valued at $217,160,000. Pentwater Capital Management LP bought a new stake in shares of Amicus Therapeutics during the 4th quarter worth about $163,760,000. Vestal Point Capital LP grew its stake in Amicus Therapeutics by 178.4% in the 2nd quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock valued at $68,187,000 after buying an additional 7,625,000 shares during the last quarter. Soros Fund Management LLC bought a new position in Amicus Therapeutics in the 4th quarter valued at about $71,200,000. Finally, UBS Group AG lifted its position in Amicus Therapeutics by 240.5% during the fourth quarter. UBS Group AG now owns 5,893,288 shares of the biopharmaceutical company’s stock worth $83,920,000 after acquiring an additional 4,162,433 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.